Cannabis Science President To Appear Today On StockGoodies.com Live Radio Show As Part of National Educational Series On The Ground-Breaking Science of Medical Cannabis At 8:30AM Eastern

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce today that it is continuing its efforts to inform the public about the importance of cannabis based medicines with an interview with Dr. Robert Melamede, Cannabis Science President and CEO on StockGoodies.com at 8:30 AM Eastern. Previously, the company has announced that has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The interview will also be available online, for those who miss the initial program.

Dr. Melamede will discuss the company's plans to bring products to market in 2010, as well as its longer-term plans for FDA approved cannabis-based pharmaceutical products. Dr. Melamede, retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, will discuss the wide variety of ailments that are currently being treated with cannabis as medical marijuana. He explained, "Cannabis Science Inc, as its name implies, is using the latest scientific techniques to develop standardized cannabis extracts that can be used in a variety of ways to help patients." He emphasized that Cannabis Science is a "patient oriented company" that works closely with the medical marijuana movement, observing what people need and what works best for them.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.